Praxis Precision Medicines is a clinical-stage genetic neuroscience company developing breakthrough therapies for patients and families affected by complex and debilitating brain disorders, including psychiatric disorders, movement disorders and rare pediatric epilepsies. These disease areas share overlapping genetics and neurocircuit biology, as well as a profound need for new therapeutic options that target the underlying cause of the disease. Praxis is advancing a pipeline of breakthrough medicines with the potential to more precisely treat brain disorders.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/04/20	$100,000,000		Blackstone Life Sciences Eventide Asset Management Novo Holdings Vida Ventures	undisclosed
07/30/20	$110,000,000	Series C-1	Adage Capital Management Avoro Capital Advisors Blackstone Life Sciences Cormorant Asset Management Eventide Asset Management Novo Holdings OCV Partners Point72 Asset Management Qatar Investment Authority Surveyor Capital Vida Ventures	undisclosed